Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).

Next Previous
Trial Profile

A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary) ; Almotriptan
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Acronyms ATOM

Most Recent Events

  • 31 May 2025 Status changed from recruiting to discontinued due to issues with recruitment
  • 21 Sep 2022 Status changed from not yet recruiting to recruiting.
  • 25 Jan 2022 Status changed from recruiting to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top